Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Combination of PS-Targeting Antibody and Radiation Resulted in 100% Survival at 6 Months Compared to 43% With Irradiation Alone in Preclinical Lung Cancer Model
TUSTIN, CA--(Marketwired - Apr 7, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy (SBRT) showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer (NSCLC) compared to irradiation alone. These data were presented yesterday at the 105(th) Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
"Data from these studies show a very impressive survival improvement and tumor burden reduction when administering an animal equivalent of bavituximab with radiation therapy compared to radiation alone," said Jeff T. Hutchins, Ph.D., vice president of preclinical research at Peregrine. "Importantly, the use of lower doses of stereotactic body radiation, a highly targeted therapeutic irradiation technique, demonstrates considerable therapeutic value in combination with bavituximab activity. Based on these results, we believe there is potential for more effective and less toxic combinations of stereotactic body radiation and investigational immunotherapies like bavituximab to work together as a potential treatment modality for patients with lung cancer."
These studies utilized rats bearing established orthotopic A549-luc NSCLC tumors, which were staged and monitored by bioluminescence imaging. Animals were treated with 3x12 Gy of radiation alone or combined with 2aG4 (mouse equivalent antibody to bavituximab) injected twice weekly. Rats treated with radiation and 2aG4 had a 100% survival rate 184 days after implantation and tumors were completely eradicated in 67% of these animals. In contrast, rats treated with radiation had a survival rate of 43% while only 12.5% of untreated rats survived. A toxicity study was conducted in which 3x12 Gy of radiation was delivered to central organs of tumor-free rats. This treatment does not appear to cause severe toxicity. These results suggest that bavituximab with radiation may result in improved clinical outcome in patients with centrally-located NSCLC. This research was conducted under grant RP120670-P4 by the Cancer Prevention Research Institute of Texas (CPRIT) awarded to The University of Texas Southwestern Medical Center.
Abstract Number: 639
Presentation Title: Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer
Presentation Time: Sunday, Apr 06, 2014, 1:00 PM - 5:00 PM